Abstract
Budd–Chiari syndrome (BCS) is characterized by an obstruction of hepatic venous outflow from small hepatic veins to inferior vena cava, caused by acute thrombosis or its fibrous sequellae. An underlying myeloproliferative neoplasm is present in 50% of cases. Clinical manifestations are widely variable, from asymptomatic to fulminant episodes. Long-term complications range from cirrhosis to hepatocellular carcinoma. Behçet’s disease (BD) is a rare recurrent inflammatory multisystemic disorder characterized by recurrent skin-mucosa lesions and systemic involvement. Vascular involvement is observed in up to 40% of the patients with BD, and it is one of the major causes of mortality and morbidity. BCS is a rare complication of BD with a frequency of < 5% among patients with vascular involvement. Immunosuppressive treatment is the cornerstone for the management of vascular involvement in BD, while anticoagulant therapy has been an issue of debate. Transjugular intrahepatic portosystemic shunt (TIPS) in severe cases of BCS—of all causes— improves survival. However, there is scarce evidence about the role of TIPS in the setting of BCS in BD. We present a case of a vascular Behçet’s disease associated with chronic Budd–Chiari syndrome with progression of thrombosis despite adequate anticoagulant and immunosuppressive treatment, successfully managed with TIPS.
Similar content being viewed by others
References
Seyahi E. Behçet’s disease: How to diagnose and treat vascular involvement. Best Pract Res Clin Rheumatol. 2016;30:279–95.
Becatti M, Emmi G, Silvestri E, et al. Neutrophil activation promotes fibrinogen oxidation and thrombus formation in Behçet’s disease. Circulation. 2015;133:302–11.
Emmi G, Becatti M, Bettiol A, et al. Behçet’s syndrome as a model of thrombo-inflammation: the role of neutrophils. Front Inmunol. 2019;10:1–8.
Becatti M, Emmi G, Bettiol A, et al. Behçet's syndrome as a tool to dissect mechanism of thrombo-inflamaation: clinical and pathogenetic aspects. Clin Exp Immunol. 2019;195:322–33.
Desbois AC, Wechsler B, Resche-Rigon M, et al. Immunosuppressants reduce venous thrombosis relapse in Behçet’s disease. Arthritis Rheum. 2012;64:2753–60.
Alibaz-Oner F, Karadeniz A, Yilmaz S, et al. Behçet disease with vascular involvement. Medicine (Baltimore). 2015;94:e494.
Garcia-Pagán JC, Buscarini E, Janssen HLA, et al. EASL clinical practice guidelines: vascular diseases of the liver. J Hepatol. 2016;64:179–202.
Valla DC. Primary Budd–Chiari syndrome. J Hepatol. 2009;50:195–203.
Ahn JK, Lee YS, Jeon CH, et al. Treatment of venous thrombosis associated with Behcet’s disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clin Rheumatol. 2008;27:201–5.
Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis. 2018;77:808–18.
García-Pagán JC, Heydtmann M, Raffa S, et al. TIPS for Budd–Chiari syndrome: long-term results and prognostics factors in 124 patients. Gastroenterology. 2008;135:808–15.
Galeano-Valle F, Demelo-Rodriguez P, Álvarez-Sala-Walther L, et al. Intracardiac thrombosis in Behçet’s disease successfully treated with immunosuppressive agents: a case of vascular pathergy phenomenon. Intractable Rare Dis Res. 2018;7:54–7.
Davatchi F, Abdollahi BS, Chams-davatchi C, et al. The saga of diagnostic/classification criteria in Behcet’s disease. JEADV. 2015;18:594–605.
Goel RM, Johnston EL, Patel KV, et al. Budd–Chiari syndrome: investigation, treatment and outcomes. Postgrad Med J. 2015;91:692–7.
Emmi G, Bettiol A, Silvestri E, et al. Vascular Behçet’s syndrome: an update. Intern Emerg Med. 2019;14:645–52.
Seyahi E, Caglar E, Ugurlu S, et al. An outcome survey of 43 patients with Budd–Chiari syndrome due to Behçet’s syndrome followed up at a single, dedicated center. Semin Arthritis Rheum. 2015;44:602–9.
Wang H, Guo X, Tian Z, et al. Intracardiac thrombus in patients with Behcet’s disease: clinical correlates, imaging features, and outcome: a retrospective, single-center experience. Clin Rheumatol. 2016;35:2501–7.
Demirelli S, Degirmenci H, Inci S, et al. Cardiac manifestations in Behcet’s disease. Intractable Rare Dis Res. 2015;4:70–5.
Park MC, Hong BK, Kwon HM, et al. Surgical outcomes and risk factors for postoperative complications in patients with Behcet’s disease. Clin Rheumatol. 2007;26:1475–80.
Saleh Z, Arayssi T. Update on the therapy of Behçet disease. Ther Adv Chronic Dis. 2014;5:112–34.
Toledo-Samaniego N, Galeano-Valle F, Pinilla-Llorente B, et al. Clinical features and management of venous thromboembolism in patients with Behçet's syndrome: a single center case-control study. Intern Emerg Med. 2019. https://doi.org/10.1007/s11739-019-02237-7.
Oblitas CM, Galeano-Valle F, Toledo-Samaniego N, et al. Budd–Chiari syndrome in Behçet’s disease successfully managed with immunosuppressive and anticoagulant therapy: a case report and literature review. Intractable Rare Dis Res. 2019;8:60–6.
Desbois AC, Rautou PE, Biard L, et al. Behcet’s disease in Budd–Chiari syndrome. Orphanet J Rare Dis. 2015;9:1–9.
Tekbas G, Oguzkurt L, Gur S, et al. Endovascular treatment of veno-occlusive Behcet’s disease. Cardiovasc Intervent Radiol. 2012;35:826–31.
Akbaş T, Imeryüz N, Bayalan F, et al. A case of Budd–Chiari syndrome with Behcet’s disease and oral contraceptive usage. Rheumatol Int. 2007;28:83–6.
Han SW, Kim GW, Lee J, et al. Successful treatment with stent angioplasty for Budd–Chiari syndrome in Behçet’s disease. Rheumatol Int. 2005;25:234–7.
Jiménez-Sáenza M, Mendoza J, Marcob F, et al. Síndrome de Budd–Chiari tratado mediante angioplastia transluminal en un paciente con enfermedad de Behçet: seguimiento a largo plazo. Med Clin (Barc). 2000;114:678–9.
Kuniyoshi Y, Koja K, Miyagi K. Surgical treatment of Budd–Chiari syndrome induced by Behcet's disease. Ann Thorac Cardiovasc Surg. 2002;8:374–80.
Orloff LA, Orloff MJ. Budd–Chiari syndrome caused by Behcet’s disease: treatment by side-to- side portacaval shunt. J Am Coll Surg. 1999;188:396–407.
Danaci M, Gül S, Yazgan Y, et al. Budd–Chiari syndrome as a complication of Behçet's syndrome. A case report Angiology. 1996;47:93–5.
Al-Dalaan A, Al-Balaa S, Ali MA, et al. Budd–Chiari syndrome in association with Behçet’s disease. J Rheumatol. 1991;18:622–6.
Bismuth E, Hadengue A, Hammel P, et al. Hepatic vein thrombosis in Behçet’s disease. Hepatology. 1990;11:969–74.
Orloff MJ, Girard B. Long term results of treatment of Budd–Chiari syndrome by side to side portacaval shunt. Surg Gynecol Obstet. 1989;168:33–41.
Wilkey D, Yocum DE, Oberley TD, et al. Budd-Chiari syndrome and renal failure in Behcet disease Report of a case and review of the literature. Am J Med. 1983;75:541–50.
Funding
None declared.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None declared.
Informed consent
We obtained the patient’s written informed consent before the submission of the manuscript.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Oblitas, CM., Toledo-Samaniego, N., Fernández-Yunquera, A. et al. Chronic Budd–Chiari syndrome in Behçet's disease successfully managed with transjugular intrahepatic portosystemic shunt: a case report and literature review. Clin J Gastroenterol 13, 572–578 (2020). https://doi.org/10.1007/s12328-020-01106-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12328-020-01106-7